NurOwn (NCT03280056) was a landmark Phase 3 clinical trial evaluating autologous mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis, conducted by BrainStorm Cell Therapeutics. This trial represented one of the most advanced stem cell approaches for neurodegenerative disease, utilizing the patient's own cells that were engineered to secrete neurotrophic factors before being reintroduced into the body[@nurown2021][@stem2020].
The trial completed in 2020 and generated important data on the safety and potential efficacy of stem cell therapy in ALS, while also providing insights into the challenges of cell-based approaches for neurodegenerative diseases. While primarily focused on ALS, the findings from NurOwn have implications for broader neurodegenerative disease research, including Parkinson's disease and other conditions where neurotrophic factor support may be beneficial.
NurOwn utilizes a sophisticated autologous stem cell approach that represents one of the most advanced cell therapy platforms in neurodegeneration[@mazzini2015]:
...
Overview
NurOwn (NCT03280056) was a landmark Phase 3 clinical trial evaluating autologous mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis, conducted by BrainStorm Cell Therapeutics. This trial represented one of the most advanced stem cell approaches for neurodegenerative disease, utilizing the patient's own cells that were engineered to secrete neurotrophic factors before being reintroduced into the body[@nurown2021][@stem2020].
The trial completed in 2020 and generated important data on the safety and potential efficacy of stem cell therapy in ALS, while also providing insights into the challenges of cell-based approaches for neurodegenerative diseases. While primarily focused on ALS, the findings from NurOwn have implications for broader neurodegenerative disease research, including Parkinson's disease and other conditions where neurotrophic factor support may be beneficial.
NurOwn utilizes a sophisticated autologous stem cell approach that represents one of the most advanced cell therapy platforms in neurodegeneration[@mazzini2015]:
Mesenchymal Stem Cell (MSC) Platform
Cell Harvest
Patient's own bone marrow is aspirated
MSCs are isolated and expanded in culture
Autologous cells avoid immune rejection concerns
Neurotrophic Factor Secretion
Cells are cultured under proprietary conditions
Induces secretion of multiple neurotrophic factors
Cells become "MSC-NTF" cells (mesenchymal stem cells - neurotrophic factors)
Neurotrophic Factors Produced[@gorio2010]
BDNF (Brain-Derived Neurotrophic Factor): Supports motor neuron survival and synaptic function
GDNF (Glial Cell Line-Derived Neurotrophic Factor): Potent motor neuron protector
HGF (Hepatocyte Growth Factor): Anti-inflammatory and neuroprotective properties
VEGF (Vascular Endothelial Growth Factor): Supports neurovascular health and angiogenesis
IGF-1 (Insulin-like Growth Factor): Promotes neuronal survival and metabolism
Delivery Method
Intrathecal injection (into spinal canal)
Allows direct access to cerebrospinal fluid circulation
Cells migrate to areas of injury in the spinal cord and brain
Therapeutic Mechanisms
The neurotrophic factors secreted by NurOwn cells work through multiple pathways[@berry2019]:
Neurotrophic Support
Provides growth factors directly to dying motor neurons
Supports axonal sprouting and synaptic function
Promotes neuronal survival in hostile microenvironment
Immunomodulation[@karussis2010]
Reduces pro-inflammatory immune responses
Modulates microglial activation
Creates favorable microenvironment for neuron survival
May reduce autoimmune components of neurodegeneration
Anti-Apoptotic Effects
Secreted factors block programmed cell death pathways
Protects remaining motor neurons from excitotoxicity
Rate of decline in ALSFRS-R (Revised ALS Functional Rating Scale)
Change from baseline to week 28
Secondary:
Slow vital capacity (SVC) change
Muscle strength (hand-held dynamometry)
Quality of life (ALSAQ-40)
CSF neurotrophic factor levels
Safety and tolerability
Results
Primary Endpoint Analysis
The trial did not meet its primary endpoint of significant difference in ALSFRS-R decline rate between treatment and placebo groups. However, pre-specified subgroup analyses suggested potential benefits in certain patient populations.
Secondary Endpoints
Mixed results across different measures
Some positive trends in slower disease progression
Safety profile was consistent with prior phases
Biomarker Findings
Elevated CSF neurotrophic factors in treatment arm
Demonstrated successful cell engraftment and function
Correlation between BDNF levels and clinical response observed
Clinical Implications
Lessons Learned
Cell Therapy Challenges
Autologous cells show patient-to-patient variability
Optimal dosing and timing remain unclear
Delivery method affects distribution
Disease Complexity
ALS involves multiple pathophysiological pathways
Single-mechanism approaches may be insufficient
Combination approaches may be needed
Trial Design Considerations
Subgroup analyses can reveal hidden benefits
Biomarker-driven enrichment strategies may improve signal detection
Longer follow-up may be needed for cell therapies
Relevance to Other Neurodegenerative Diseases
While NurOwn targeted ALS, the platform has implications for:
[NurOwn Phase 3 Trial in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33471056/)
[Stem Cell Therapy for Neurodegenerative Disease (2020)](https://doi.org/10.1016/j.stem.2020.12.011)
[Mazzini et al., Mesenchymal stem cells in ALS (2015)](https://pubmed.ncbi.nlm.nih.gov/25617921/)
[Karussis et al., Safety and immunological effects of MSC (2010)](https://pubmed.ncbi.nlm.nih.gov/20444656/)
[Berry et al., Stem cell therapy for neurodegeneration (2019)](https://doi.org/10.1038/s41582-019-0227-8)
[Gorio et al., MSC secretome and neuroprotection (2010)](https://doi.org/10.1016/j.expneurol.2010.03.016)
Overview
NurOwn (NCT03280056) was a landmark Phase 3 clinical trial evaluating autologous mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis, conducted by BrainStorm Cell Therapeutics. This trial represented one of the most advanced stem cell approaches for neurodegenerative disease, utilizing the patient's own cells that were engineered to secrete neurotrophic factors before being reintroduced into the body[@nurown2021][@stem2020].
The trial completed in 2020 and generated important data on the safety and potential efficacy of stem cell therapy in ALS, while also providing insights into the challenges of cell-based approaches for neurodegenerative diseases.
Trial Details
| Attribute | Value | |-----------|-------| | NCT Number | NCT03280056 | | Phase | Phase 3 | | Status | Completed (results published) | | Sponsor | BrainStorm Cell Therapeutics | | Enrollment | 196 patients | | Duration | 28 weeks treatment | | Study Period | 2017-2020 | | Locations | US (multiple centers) |
Mechanism of Action
NurOwn utilizes a sophisticated autologous stem cell approach:
Mesenchymal Stem Cell (MSC) Platform
Cell Harvest
Patient's own bone marrow is aspirated
MSCs are isolated and expanded in culture
Autologous cells avoid immune rejection concerns
Neurotrophic Factor Secretion
Cells are cultured under proprietary conditions
Induces secretion of multiple neurotrophic factors
Cells become "MSC-NTF" cells
Neurotrophic Factors Produced
BDNF (Brain-Derived Neurotrophic Factor): Supports motor neuron survival
GDNF (Glial Cell Line-Derived Neurotrophic Factor): Potent motor neuron protector
HGF (Hepatocyte Growth Factor): Anti-inflammatory and neuroprotective
VEGF (Vascular Endothelial Growth Factor): Supports neurovascular health